Amplia Therapeutics (ASX:ATX) was informed by the US Patent and Trademark Office that a patent describing the specific chemical form of its narmafotinib drug candidate, being used in ongoing clinical trials in advanced pancreatic cancer, protecting narmafotinib, had been allowed in the US, according to a Tuesday Australian bourse filing.
Narmafotinib is an inhibitor of the protein focal adhesion kinase, which is overexpressed in pancreatic cancer.
A formal "Notification of Grant" of the patent in the US is expected in the coming months.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments